INDICATION

ABECMA (idecabtagene vicleucel) is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.

This website is best viewed using the horizontal display on your tablet device.

This website is best viewed using the vertical display on your mobile device.

Cell Therapy 360®

Dedicated to providing solutions-oriented support and knowledge to help patients
throughout the CAR T cell therapy journey

Bristol Myers Squibb’s Cell Therapy 360® program supports patients and caregivers throughout their treatment journey, from enrollment through the initial post-infusion monitoring period, with referral resources, patient support navigators, logistical support*, financial support*, and wearable technology for post-infusion monitoring.

*Eligibility requirements may apply.

Post-infusion monitoring support

Patients can receive a disposable wearable technology during the initial post-infusion monitoring period to help track their temperature in real time through their smartphone when outside the treatment center.

Patients are instructed to call their healthcare provider or go to the hospital if their temperature is 100.4°F/38°C or higher.

Cell Therapy 360 enrollment

Patients may enroll in support programs offered through Cell Therapy 360 after a certified CAR T treatment center determines that ABECMA® is the right treatment for them.

Cell Therapy 360 Logo

Call us at 1-888-805-4555

Visit us at CellTherapy360.com

Learn more about ABECMA®
efficacy & safety

Find a certified
treatment center near you

CAR=chimeric antigen receptor.